{"684663":{"#nid":"684663","#data":{"type":"event","title":"PhD Proposal by  Sebastian Rudden","body":[{"value":"\u003Cp\u003ESebastian Rudden\u003Cbr\u003EBME PhD Proposal Presentation\u003Cbr\u003E\u003Cbr\u003E\u003Cstrong\u003EDate\u003C\/strong\u003E: 2025-09-16\u003Cbr\u003E\u003Cstrong\u003ETime\u003C\/strong\u003E: 10:00 am - 12:00 pm EST\u003Cbr\u003E\u003Cstrong\u003ELocation \/ Meeting Link\u003C\/strong\u003E: HSRB II, N600\u003Cbr\u003E\u003Cstrong\u003ECommittee Members:\u003C\/strong\u003E\u003Cbr\u003EJames Dahlman, PhD (Advisor); Brandon Dixon, PhD; Hanjoong Jo, PhD; Yonggang Ke, PhD; Hyejin Kim, PhD\u003Cbr\u003E\u003Cbr\u003E\u003Cbr\u003E\u003Cstrong\u003ETitle\u003C\/strong\u003E: A Novel Amino Lipid Series for mRNA Delivery, validated in pseudo-clinical trials\u003Cbr\u003E\u003Cbr\u003E\u003Cstrong\u003EAbstract:\u003C\/strong\u003E\u003Cbr\u003ELipid nanoparticles (LNPs) are the most clinically advanced delivery method for mRNA, which has the potential to treat myriad diseases. There is an ongoing need for novel lipids which are highly potent, safe, and minimize off-target delivery. First, I will walk through how we screened dozens of chemically distinct ionizable lipids (which are the heart of LNPs) to obtain a lipid class which meets all these criteria. Next, I will demonstrate extensive mouse validation showing that our lead LNP27 is 10x more potent than Moderna\u2019s vaccine LNP, while maintaining an excellent on\/off target ratio and safety profile. We finally demonstrate functional delivery of a reporter protein in non-human primates (NHPs) at a low dose. This pseudo-clinical trial approach minimizes loss of life by using NHPs that are already scheduled for euthanasia due to chronic illness. Having validated LNP27 thoroughly, I next aim to examine how it can deliver a therapeutic cargo. CAR T therapy has revolutionized cancer treatment, saving the lives of many relapsed patients who otherwise had a bleak prognosis. However, the current standard-of-care involves immense cost (~$0.5 million) and other challenges. LNPs have the potential to facilitate\u0026nbsp;in vivo\u0026nbsp;CAR therapy, bypassing many of these challenges. If in vivo\u0026nbsp;CAR continues to work, it has the potential to once again revolutionize not just CAR therapy, but cancer treatment at large. This is no exaggeration - last month, AbbVie acquired an\u0026nbsp;in vivo\u0026nbsp;CAR company (using LNPs) for $2 billion. We believe that by using our potent LNPs combined with advanced preclinical models, we can substantially support\u0026nbsp;in vivo\u0026nbsp;CAR efforts, thereby helping to make this lifesaving therapy more accessible. To this end, I will share preliminary data showing that LNP27 can generate CAR in mice\u0026nbsp;in vivo\u0026nbsp;and in NHP spleen cells\u0026nbsp;ex vivo, and propose how we will use LNP27 to generate\u0026nbsp;in vivo\u0026nbsp;panCAR (all immune cells activated and ready to fight cancer) in end-of-life NHPs to produce a therapeutic effect.\u003C\/p\u003E","summary":"","format":"limited_html"}],"field_subtitle":"","field_summary":[{"value":"\u003Cp\u003EA Novel Amino Lipid Series for mRNA Delivery, validated in pseudo-clinical trials\u003Cbr\u003E\u003Cbr\u003E\u0026nbsp;\u003C\/p\u003E","format":"limited_html"}],"field_summary_sentence":[{"value":"A Novel Amino Lipid Series for mRNA Delivery, validated in pseudo-clinical trials"}],"uid":"27707","created_gmt":"2025-09-09 12:15:38","changed_gmt":"2025-09-09 12:15:38","author":"Tatianna Richardson","boilerplate_text":"","field_publication":"","field_article_url":"","field_event_time":{"event_time_start":"2025-09-16T10:00:00-04:00","event_time_end":"2025-09-16T12:00:00-04:00","event_time_end_last":"2025-09-16T12:00:00-04:00","gmt_time_start":"2025-09-16 14:00:00","gmt_time_end":"2025-09-16 16:00:00","gmt_time_end_last":"2025-09-16 16:00:00","rrule":null,"timezone":"America\/New_York"},"location":"HSRB II, N600 ","extras":[],"groups":[{"id":"221981","name":"Graduate Studies"}],"categories":[],"keywords":[{"id":"102851","name":"Phd proposal"}],"core_research_areas":[],"news_room_topics":[],"event_categories":[{"id":"1788","name":"Other\/Miscellaneous"}],"invited_audience":[{"id":"78771","name":"Public"}],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[],"email":[],"slides":[],"orientation":[],"userdata":""}}}